8:55–9:20

Abstract LBA2

Impact on overall survival (OS)   with chemohormonal therapy versus hormonal therapy for hormone sensitive   newly metastatic prostate cancer (mPrCa): An ECOG-led phase III randomized   trial.

一项ECOG领导的 III期随机临床试验：激素敏感的新发转移性前列腺癌患者（mPrCa）接受化疗联合内分泌治疗对比单用内分泌治疗对于总生存期(OS)的影响。

戴  波(Bo Dai)

Abstract 5003

Immediate versus deferred   initiation of androgen deprivation therapy in prostate cancer patients with   PSA-only relapse.

PSA复发的前列腺癌患者接受立即雄激素剥夺治疗与延迟雄激素剥夺治疗的比较。

Abstract 5008

Phase 3, randomized,   placebo-controlled trial of orteronel (TAK-700) plus prednisone in patients   (pts) with chemotherapy-naïve metastatic castration-resistant prostate cancer   (mCRPC) (ELM-PC 4 trial).

三期、随机、安慰剂对照临床试验（ELM-PC 4试验）：orteronel(tak   - 700)联合强的松治疗未接受过化疗的转移性去势抵抗型前列腺癌患者（mCRPC）的研究。

9:20–9:30

专家评述

Discussion   Topic: Feasibility of combined therapy for patients with hormone-sensitive   prostate cancer

讨论主题：对激素敏感型前列腺癌患者进行联合治疗的可行性

何志嵩(Zhi-Song He)

9:30–9:35

讨论(Q &   A)

叶定伟(Ding-Wei Ye)

马建辉(Jian-Hui Ma)

何志嵩(Zhi-Song   He)